300
Participants
Start Date
January 20, 2022
Primary Completion Date
December 31, 2023
Study Completion Date
December 31, 2024
TACE
Procedure of TACE is standardized.
Lenvatinib
8mg; p.o.; q.d.
Anti-PD-1 monoclonal antibody
Advanced HCC Patients treated with TKI plus anti-PD-1 monoclonal antibody as systemic therapy were recruited. Anti-PD-1 monoclonal antibodies include pembrolizumab (200 mg, q3w), nivolumab (3mg/kg, q2w), camrelizumab (200mg, q2w), tislelizumab (200mg, q3w), sintilimab (200 mg, q3w), or toripalimab (240mg, q3w).
Bevacizumab Biosimilar IBI305 plus sintilimab
Bevacizumab Biosimilar IBI305 (15mg/kg, q3w), and sintilimab (200 mg, q3w)
Bevacizumab plus Atezolizumab
Bevacizumab (15mg/kg, q3w) plus Atezolizumab (1200 mg, q3w)
apatinib plus camrelizumab
Apatinib(250 mg; p.o.; q. d.); camrelizumab (200 mg; iv drip; q2w)
Sorafenib
400mg; p.o. bid
Donafenib
200mg; p.o. bid
Regorafenib
160 mg; p.o.; q.d.
RECRUITING
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan
RECRUITING
Optical Valley branch of Tongji hospital, Wuhan
RECRUITING
The Second Affiliated Hospital of Fujian Medical University, Quanzhou
RECRUITING
Sino-French branch of Tongji hospital, Wuhan
Collaborators (1)
Chinese Cooperative Group of Liver Cancer
OTHER
Chen Xiao-ping Foundation for the Development of Science and Technology of Hubei Province
OTHER
The Second Affiliated Hospital of Fujian Medical University
OTHER
Geneplus-Beijing Co. Ltd.
INDUSTRY
Haplox Biotechnology Co., Ltd.
INDUSTRY
Tongji Hospital
OTHER